Page 3 - Remunity Pump News Today

Nicollet Investment Management Inc. increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 2.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,788 shares of the biotechnology company’s stock after acquiring an additional 115 shares […]

Leerink Partnrs reissued their outperform rating on shares of United Therapeutics (NASDAQ:UTHR – Free Report) in a report published on Monday, PriceTargets.com reports. Leerink Partnrs also issued estimates for United Therapeutics’ Q4 2023 earnings at $4.28 EPS, FY2023 earnings at $19.79 EPS, Q1 2024 earnings at $5.07 EPS, Q2 2024 earnings at $5.25 EPS, Q3 […]

Weil Company Inc. lowered its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 0.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 48,020 shares of the biotechnology company’s stock after selling 246 shares during the quarter. United Therapeutics comprises 5.4% of Weil […]

L2 Asset Management LLC trimmed its position in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 95.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 579 shares of the biotechnology company’s stock after selling 11,438 shares during the […]

Assenagon Asset Management S.A. reduced its stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 81.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,133 shares of the biotechnology company’s stock after selling 399,050 shares during the quarter. Assenagon Asset Management […]

LSV Asset Management raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 1.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 383,068 shares of the biotechnology company’s stock after acquiring an additional 3,700 shares during the […]

Shares of United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) have been given an average recommendation of “Buy” by the eight research firms that are currently covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued a […]

United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) has been given a consensus rating of “Buy” by the eight research firms that are covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have covered the stock in the last […]

Forsta AP Fonden lessened its stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 70.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,500 shares of the biotechnology company’s stock after selling 5,900 shares during the period. Forsta AP […]

United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $227.97, for a total transaction of $1,367,820.00. Following the completion of the transaction, the executive vice president now […]